fda drug safety communication semaglutide naion 2025 just got FDA-approved for kidney disease. This changes everything. January 2025. The approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in type 2 diabetes with CKD. This New lawsuits claim that certain

Heres the short answer: Since Ozempic and Wegovy received FDA approval for type 2 diabetes and weight loss, respectively, they are generally eligible for payment through HSA/FSA accounts

Appetite loss, headaches, and fatigue are also reported

Interventions such as prebiotics, probiotics, antidiabetic drugs, and bariatric surgery have also been shown to modulate the gut microbiota, reinforcing the idea that targeting the microbiota may enhance the outcomes of GLP-1-based therapies [82]

Some of these stress-reducing tools may include: Meditation Music Yoga Physical activity Social interactions Sleep Journaling Therapy Vacations Hobbies Other forms of self-care Say No